In this study, we successfully detected three clinically valuable protein biomarkers on CTCs, namely, PD-L1, HER2, and VEGF, from patients with NSCLC, breast cancer, and pancreatic adenocarcinoma (PAAD) (Figure 6A). This evidence concerns the gene ERBB2 and breast carcinoma.